quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM)

View original at finance.yahoo.com
Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM) Looking back on mixed or offshore upstream e&p stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including SM Energy (NYSE:SM) and its peers…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Seadrill Q1 2026 revenues of $358 million outperformed analysts' expectations by 7.2%, with beats also on EPS and EBITDA estimates.

    60% confidence

  • As a group, the 21 mixed or offshore upstream E&P stocks reported Q1 revenues that missed analysts' consensus estimates by 5%.

    60% confidence

  • SM Energy Q1 2026 revenues of $1.48 billion exceeded analysts' expectations by 5.8%, with beats also on EPS and EBITDA estimates.

    60% confidence

  • On average, shares of the 21 tracked mixed or offshore upstream E&P companies are down 6.8% since the latest earnings results.

    60% confidence

  • SM is off to an outstanding start in 2026.

    60% confidence

  • Smaller or niche E&P companies face headwinds including higher operational and geological risks, limited scale, constrained capital market access, and disproportionate regulatory and ESG risks.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM) — Source | Via News | pt.VIA.NEWS